These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26302859)

  • 21. Investigation into the influence of primary crystallization conditions on the mechanical properties and secondary processing behaviour of fluticasone propionate for carrier based dry powder inhaler formulations.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Pharm Res; 2012 Apr; 29(4):994-1006. PubMed ID: 22161310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods for reduction of cohesive forces between carrier and drug in DPI formulation.
    Desai SS; Aher AA; Kadaskar PT
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1589-98. PubMed ID: 23050727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dry powder inhaler formulation.
    Telko MJ; Hickey AJ
    Respir Care; 2005 Sep; 50(9):1209-27. PubMed ID: 16122404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterisation of adhesional properties of lactose carriers using atomic force microscopy.
    Louey MD; Mulvaney P; Stewart PJ
    J Pharm Biomed Anal; 2001 Jun; 25(3-4):559-67. PubMed ID: 11377036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers.
    James J; Crean B; Davies M; Toon R; Jinks P; Roberts CJ
    Int J Pharm; 2008 Sep; 361(1-2):209-21. PubMed ID: 18577435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?
    de Boer AH; Chan HK; Price R
    Adv Drug Deliv Rev; 2012 Mar; 64(3):257-74. PubMed ID: 21565232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lactose characteristics and the generation of the aerosol.
    Pilcer G; Wauthoz N; Amighi K
    Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of drug particle surface energetics and young's modulus by atomic force microscopy and inverse gas chromatography.
    Davies M; Brindley A; Chen X; Marlow M; Doughty SW; Shrubb I; Roberts CJ
    Pharm Res; 2005 Jul; 22(7):1158-66. PubMed ID: 16028017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of Electrostatic Behavior of Dry Powder-Inhaled Model Formulations.
    Jetzer MW; Morrical BD
    J Pharm Sci; 2019 Sep; 108(9):2949-2963. PubMed ID: 31004652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A nanoscale study of particle friction in a pharmaceutical system.
    Bunker MJ; Roberts CJ; Davies MC; James MB
    Int J Pharm; 2006 Nov; 325(1-2):163-71. PubMed ID: 16875789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of Dry Powders to the Lungs: Influence of Particle Attributes from a Biological and Technological Point of View.
    Zellnitz S; Roblegg E; Pinto J; Fröhlich E
    Curr Drug Deliv; 2019; 16(3):180-194. PubMed ID: 30360739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of void forming index (VFI): Detection of the effect of physical properties of dry powder inhaler formulations on powder cohesion.
    Maruyama S; Ando S; Yonemochi E
    Int J Pharm; 2020 Oct; 588():119766. PubMed ID: 32800937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the effects of blending, physicochemical properties, and their interactions on the performance of carrier-based dry powders for inhalation - A review.
    Kaialy W
    Adv Colloid Interface Sci; 2016 Sep; 235():70-89. PubMed ID: 27291646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DEM analysis of the effect of particle-wall impact on the dispersion performance in carrier-based dry powder inhalers.
    Yang J; Wu CY; Adams M
    Int J Pharm; 2015 Jun; 487(1-2):32-8. PubMed ID: 25845718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers.
    Shur J; Pitchayajittipong C; Rogueda P; Price R
    Ther Deliv; 2013 Aug; 4(8):925-37. PubMed ID: 23919472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation of Biopharmaceutical Dry Powder Inhaler Using the Void Forming Index (VFI) to Detect and Avoid Powder Caking in Dry Powder Inhaler Formulations.
    Maruyama S; Miyajima M; Yonemochi E
    Chem Pharm Bull (Tokyo); 2022; 70(4):245-253. PubMed ID: 35370200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.